SpectraCure’s current main focus are the clinical phase 2 study and the development of the new generation of SpectraCure’s treatment system. The clinical trial, designated for treatment of patients with recurrent prostate cancer using the company’s photodynamic therapy (PDT) technology, is ongoing at our partner hospitals. The recruitment of patients for the fall in the phase 2 study is going on continuously.
During summer, the first units of the new generation PDT system were installed and tested in SpectraCure’s laboratory in Lund. The tests will continue coming weeks and at the same time the regulatory work is starting, to obtain authority approval to use the systems in clinical trials.
Hopefully,we can release the new generation PDT system to be used in the clinical trials and possibly also fast track, after the authorities approval (FDA), comments Masoud Khayyami, CEO.
During summer, work has also been done writing a patent application to protect central parts of the construction on which the new PDT system is based.
For further information, contact:
SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46(0) 70 815 21 90
Certified Adviser is G&W Fondkommission, e-mail: email@example.com, phone: +46-(8)-503 000 50.
SpectraCure in short
SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region
Se fullständiga pressmeddelande och andra nyheter från detta bolag hos Cision News